Clinical trial Recruiting at 3 sites Interventional Ages 18 and up

The Coma Family Program: a resilience program for caregivers of patients with severe brain injury

Official title: The Coma Family Program (COMA-F): A Multi-site Clinical Trial of a Resilience Program for Caregivers of Patients With Severe Acute Brain Injury

Run by Icahn School of Medicine at Mount Sinai · NCT07331324 · Data updated 2026-11-12

This program tests whether the Coma Family Program can better reduce emotional distress in caregivers of patients with severe acute brain injury compared to a health education control.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment150 (estimated)
SponsorIcahn School of Medicine at Mount Sinai
Academic / other
Locations4 sites (Baltimore, Maryland and 3 other locations)
StatusRecruiting
StartedSeptember 28, 2026
Main results expectedAugust 2030
Study endsAugust 2030
Registry record updatedOctober 29, 2026
Trial IDNCT07331324 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are English-speaking adult informal caregivers of ICU patients with severe acute brain injury who show elevated distress on the HAM-D or HAM-A scales.

Probably not a fit

Caregivers who do not have elevated distress or who are not primary caregivers may derive little or no benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study targets informal caregivers of patients with severe acute brain injury who are experiencing emotional distress. Participants are randomized to receive one of two versions of the Coma Family Program, or a health education control, with the aim of reducing depression and anxiety symptoms. The program focuses on building resilience and coping strategies for caregivers during the patient’s ICU hospitalization and recovery trajectory. Eligibility requires caregiver age 18+, English fluency, and elevated distress on the Hospital Anxiety and Depression Scale, with the patient meeting criteria for severe brain injury and ICU admission. The study is conducted across multiple sites including Maryland, Boston, and New York, with the Icahn School of Medicine at Mount Sinai leading the effort.

Why it matters

Potential benefit: If successful, caregivers may experience less emotional distress and improved resilience while supporting patients with severe brain injuries.

How similar studies have gone: Previous work in caregiver support programs suggests potential for distress reduction, but effectiveness can vary by program and population.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* 18 years or older - study population
* English fluency and literacy - measures and intervention are in English
* Screens positive for emotional distress on either depression or anxiety subscales (\>7) of the Hospital Anxiety and Depression scale - study population (caregivers must be at-risk for chronic distress via heightened acute distress)
* Confirmed by the clinical team as the primary caregiver of a patient who has been admitted to an intensive care unit (ICU) with a severe acute brain injury with the following characteristics:

  * 18 years or older - study population
  * Admitted with ischemic stroke, intracerebral hemorrhage, subarachnoid hemorrhage, traumatic brain injury, or hypoxic-ischemic encephalopathy - study population
  * Glasgow Coma Scale score below 9 (in judgement of the clinical team) while not intubated or an inability to follow meaningful commands while intubated at any point during the hospitalization for \> 24 consecutive hours due to the brain injury itself and not a confounding factor (e.g., sedation or seizures) - study population
  * Still alive in ICU at the time the clinical team approaches the caregiver about possible recruitment - excludes caregivers of those that passed away as would require a different intervention (e.g., grieving intervention)
  * Has been committed to or has already received long-term life-sustaining treatments including tracheostomy and/or percutaneous endoscopic or surgical gastrostomy tube placement (trach or PEG) - study population; at time of enrollment patients can be in various early stages of cognitive/functional recovery from initial coma, but all were severe enough to require trach and/or PEG
  * Has a prognosis for survival of greater than 3 months and does not have a concurrent diagnosis of a terminal illness or injury as judged by the clinical team - as in "d"; such caregivers would require different intervention
  * Is still in ICU or has been transferred to a lower level of care (e.g., stepdown) for \<7 days at the time of consent - study population; we aim to begin the intervention when caregivers are acutely distressed in the context of the patient's ICU stay or shortly after the ICU stay (i.e., within 7 days of leaving)

Exclusion Criteria:

• Serious mental illness, substance misuse, or active suicidal intent or plan - requires higher level of care

Where it's running

  • University of Maryland School of Medicine
    Baltimore, Maryland, United States
    Recruiting
  • Mount Sinai Health System
    New York, New York, United States
    Recruiting
  • University of North Carolina School of Medicine
    Chapel Hill, North Carolina, United States
    Recruiting
  • Massachusetts General Hospital
    Boston, Massachusetts, United States
    Withdrawn

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.